News Focus
News Focus
icon url

La Flaca

09/19/25 12:08 PM

#501075 RE: boi568 #501074

Circumstantial observations that are hopeful. Like us novices, these experts are looking/wanting to approve an effective drug that is also safe. They are human and just want to make sure the signal is real. So many doctors have seen/reviewed/tested the data. They all validated the signal. My God, let it be and let not the desire for a perfectly designed trial get in the way of approval of a good, working MOA.
icon url

La Flaca

09/19/25 12:18 PM

#501078 RE: boi568 #501074

So close to the finish line and yet still seems out of reach. But this very well could be approved even conditionally. Benefit outweighs the risk, IMO. Praying they think so as well.
icon url

Investor2014

09/19/25 12:22 PM

#501079 RE: boi568 #501074

Can’t put much weight on such hearsay. Of course anyone representing Anavex will say it’s going great.
icon url

boi568

09/19/25 11:07 PM

#501138 RE: boi568 #501074

For what it's worth, I just had this Q and A with ChatGTP, which appears to confirm my earlier conclusion about the significance of Anavex's apparently successful passing of the first clock stop:

"What is the key moment in the EMA MAA process between the validation of the MAA and the approval/disapproval recommendation?"

The key moment in the EMA centralized Marketing Authorisation Application (MAA) procedure between validation and the final CHMP opinion (approval/disapproval recommendation) is the CHMP’s assessment and adoption of the List of Questions (LoQ) at Day 120 of the procedure.

Here’s the flow in context:

1. Validation (Day 0 start) – EMA confirms the application is complete enough to be assessed.
2. Day 80 – Rapporteur and co-rapporteur assessment reports are circulated within CHMP.
3. Day 120 – CHMP adopts the List of Questions (LoQ):

* This is the pivotal milestone.
* The CHMP consolidates all major objections, requests for additional data, and clarifications.
* The procedure then stops (“clock-stop”) to allow the applicant to respond.

🔑 This is the moment the applicant learns whether the application is on track or faces fundamental obstacles.
4. Day 121+ – Applicant prepares responses (clock-stop, variable length).
5. Day 180 – After resubmission, rapporteurs issue an updated assessment. If major issues remain, a List of Outstanding Issues (LoOI) is adopted. Another clock-stop may follow.
6. Day 210 – The CHMP reaches its final opinion (positive or negative).

So, while there are several important milestones, Day 120 (LoQ adoption) is the decisive “turning point,” because it determines whether the applicant can realistically address concerns and move toward approval.